Gilles Salles
吉尔·萨莱斯
MD, PhD
Chief, Lymphoma Service淋巴瘤科主任
👥Biography 个人简介
Prof. Gilles Salles is an internationally renowned expert in follicular lymphoma and B-cell malignancies. He led the RELEVANCE trial comparing R² (lenalidomide plus rituximab) versus R-CHOP in frontline follicular lymphoma and has been a global leader in evaluating obinutuzumab and novel immunotherapy combinations.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
RELEVANCE Trial and Follicular Lymphoma Frontline Therapy
Led the phase III RELEVANCE trial comparing lenalidomide-rituximab (R²) to R-CHOP/R-CVP in untreated follicular lymphoma, providing essential evidence that guided frontline treatment decisions.
Representative Works 代表性著作
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma (RELEVANCE)
New England Journal of Medicine (2018)
Phase III trial demonstrating comparable efficacy of R² and standard immunochemotherapy, establishing lenalidomide-based regimens as a chemo-free option in frontline follicular lymphoma.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 吉尔·萨莱斯 的研究动态
Follow Gilles Salles's research updates
留下邮箱，当我们发布与 Gilles Salles（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment